AmMax is developing first-in-class or best-in-class therapeutics targeting a range of oncology diseases with significant unmet needs . Clinical trials are needed to assess the efficacy and safety of these experimental therapies.

​

AmMax is executing a multi-center, global Phase 2 clinical study program to assess the efficacy and safety of AMB-05X in patients with tenosynovial giant cell tumor (TGCT).

​

Study Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor

​

AmMax has completed the following study in patients with tenosynovial giant cell tumor (TGCT)

​

Study Title: An adaptive, multicenter, open-label study to evaluate the safety, efficacy, and pharmacokinetics of intra-articular AMB-05X injection in subjects with tenosynovial giant cell tumor of the knee.

​

If you are interested in participating in the trial or have questions, please feel free to contact us at clinical@ammaxbio.com.